Want to join the conversation?
Biopharmaceutical giant $GILD posted lower earnings in 2Q16 as a result of lower provision for income taxes. Net income was $3.5Bil or $2.58 per diluted share vs. $4.5Bil or $2.92 per diluted share in 2Q15. Non-GAAP diluted EPS excluding items was $3.08 for the quarter. Revenues fell 5.6% to $7.8Bil vs. 2Q15, hurt by lower anti-viral product sales.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.